Logos for IncyteCARES & Jakafi (ruxolitinib) tablets

IncyteCARES for Jakafi is a program for residents
of the United States and Puerto Rico.

For Healthcare Professionals Arrow

About IncyteCARES for Jakafi

Call us at 1-855-452-5234.

Our IncyteCARES for Jakafi team is available Monday through Friday, 8 AM–8 PM ET.

No. Anyone can call IncyteCARES for Jakafi for general information.

No. Some patients who have been prescribed Jakafi may not be eligible to enroll in the IncyteCARES for Jakafi program or to receive some of the services or support we offer. Contact IncyteCARES for Jakafi for more details and to determine if you’re eligible. Our team can be reached at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

Enrollment in the IncyteCARES for Jakafi program for eligible patients lasts for one year. You can re-enroll each year (we’ll remind you when it’s time!) and can continue to be part of the program for as long as you’re taking Jakafi.

Watch our videos about real IncyteCARES for Jakafi patient experiences.

Filling Your Prescription

No. Typically your specialty pharmacy will contact you each month to see if you would like a refill of your Jakafi. If you don’t receive this call, you can call your specialty pharmacy directly or contact IncyteCARES for Jakafi.

Call IncyteCARES for Jakafi about any insurance changes, and we can help you understand your new coverage. We can also determine if you are now, or are still, eligible for our IncyteCARES for Jakafi Savings Program or other financial assistance programs. Your new insurance company may require you to use a different specialty pharmacy to fill your prescription. We can help you change pharmacies if needed and coordinate your medicine delivery from the new pharmacy.

Yes. You can always send prescriptions directly to a participating Jakafi specialty pharmacy. Keep in mind, however, that IncyteCARES for Jakafi can offer helpful services, particularly if you don't have prescription drug coverage.

Check with your specialty pharmacy. It may provide a refill reminder service.

Jakafi prescriptions can be filled by these specialty pharmacies. Note that your insurance company may require you to use certain pharmacies to fill your prescription.

Financial Assistance Options

To qualify for the Savings Program, patients must meet the following criteria:

  • Have commercial prescription drug coverage. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for Jakafi for an FDA-approved use

Read complete terms and conditions here.

For more information, call IncyteCARES for Jakafi at 1-855-452-5234.

You can ask your prescribing Healthcare Professional, Specialty Pharmacist, or IncyteCARES for Jakafi to check your eligibility and enroll you in the program.

Read complete terms and conditions here.

For more information, call IncyteCARES for Jakafi at 1-855-452-5234.

Once your Healthcare Professional submits your completed enrollment form, or you answer a few questions on a call with an IncyteCARES for Jakafi representative, eligibility is determined right away. If you are eligible, a program member number is typically issued immediately. Either you or our team can share this member number with your specialty pharmacy, so it can be applied to your prescription for Jakafi.

No. Your enrollment in the program will automatically renew each year. You do not need to re-enroll. You should, however, contact IncyteCARES for Jakafi if your prescription insurance plan changes, so we can update your information.

The Patient Assistance Program (PAP) program helps eligible patients who do not have prescription drug insurance and have trouble affording their out-of-pocket costs for Jakafi. No purchase contingencies or other obligations apply.

To qualify, you must:*

  • Be confirmed as eligible for and enrolled in IncyteCARES for Jakafi
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for Jakafi for an FDA-approved use
  • Meet one of these 3 criteria:

    Uninsured

    1. You have no prescription drug coverage and meet household income criteria

    Underinsured

    1. text
    2. You have Medicare Part D and meet household income criteria and additional program requirements
    3. You have any other type of prescription drug insurance (commercial, Medicaid, etc) but have exhausted or been denied coverage for Jakafi and meet household income criteria

For more information, call IncyteCARES for Jakafi at 1-855-452-5234.

*Terms and conditions apply. Terms of this program may change at any time.

Conditional approval for the PAP is provided in 1 to 2 business days after we receive a patient's completed enrollment form. That means patients are approved for a supply of free medicine for 90 days. In the meantime, patients must send us proof of current household income. Eligible patients are fully approved for the PAP when proof of income criteria are confirmed.

You must document your current household income by submitting one of the following: your most recent federal income tax return, your most recent W-2 earnings statement from your employer, or one month of recent pay stubs.

Once we receive your completed PAP enrollment form, you will be given "conditional approval" for the program. This means patients are temporarily approved for the program, for up to 90 days, until we can review and evaluate the financial information (household size and current annual income) you must send to IncyteCARES for Jakafi.

Yes. If you are enrolled in Medicare but do not have Medicare Part D prescription drug coverage, you are required to reapply for PAP each calendar year. If you are not uninsured and not Medicare-eligible, you are required to reapply each year after your original approval date.

Understanding Insurance Coverage

Once we receive your insurance information, we can research your coverage for Jakafi right away. In most cases, we’ll call you with this information within 2 business days. If there is a delay, we’ll notify you and/or your Healthcare Professional within that time frame.

Many insurance plans require prior authorization before they will approve coverage for Jakafi. This means they require your Healthcare Professional to send them additional information about your condition and why Jakafi is being prescribed. Based on the additional details, they will determine coverage. In most cases, this extra step delays their coverage approval by just a few days. In the unusual event that your insurance company delays their coverage decision by more than a few business days, we may offer you a free short-term supply of Jakafi through our IncyteCARES for Jakafi Temporary Access Program.

Your enrollment in the IncyteCARES for Jakafi program lasts for one year. That means you must re-enroll annually by submitting a new enrollment form. At that time, we also have to reconfirm your insurance coverage for Jakafi.

Please contact IncyteCARES for Jakafi if your insurance coverage changes or is lost or if you have a life-changing event such as a job loss or other change in household income. We can determine any changes in your coverage for Jakafi or your out-of-pocket costs. We can also find out if your specialty pharmacy is still within network for your insurer and can communicate any changes to them. If you need to change specialty pharmacies, we can help with that as well.

phone support icon

Need Help?

Our IncyteCARES for Jakafi team is available Monday through Friday, 8 AM–8 PM ET
Call us at 1-855-452-5234

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (GVHD) who have taken one or two types of treatments and they did not work well enough.

IMPORTANT SAFETY INFORMATION

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (GVHD) who have taken one or two types of treatments and they did not work well enough.

IMPORTANT SAFETY INFORMATION

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.